Invicta Diagnostic IPO (Dec 2025): ₹28.12 Cr Issue, 90% Revenue Growth, and a Radiology Revolution in Scrubs!
1. At a Glance
Invicta Diagnostic Ltd. is the kind of startup that popped out of Mumbai’s diagnostic cauldron with a PET scanner in one hand and an IPO prospectus in the other. With a fresh issue worth ₹28.12 crore, this radiology-pathology hybrid is stepping into the NSE SME ring from December 1 to 3, 2025. The price band sits between ₹80 and ₹85, and with a lot size of 1,600 shares, the minimum retail investment clocks in at a not-so-casual ₹2.72 lakh.
The company’s financials read like a pleasant surprise in the diagnostic space: revenue up 90% YoY, PAT up 30%, and EBITDA margin around 30.6%. With an ROE of 44.28%, the balance sheet seems juiced on protein powder, not plasma. Pre-IPO, Invicta was valued at roughly ₹106.86 crore, with a P/E ratio near 14.5×, making it cheaper than a CT scan but costlier than your annual health check-up package.
Headquartered in Mumbai and trading under the brand PC Diagnostics, this young company already runs 7 centres, employs 157 people, and boasts a hub-and-spoke model that’s more networked than your average MBA alumni WhatsApp group.
2. Introduction
Mumbai’s diagnostic scene is more crowded than a local train at 8:45 a.m. — with Thyrocare, Metropolis, SRL, and every lane having its own “Dr. Lal” signboard. Into this comes Invicta Diagnostics, the cool new radiologist on the block. Incorporated in 2021, Invicta’s pitch is simple yet bold: “We’ll do everything from X-rays to genetic panels under one brand, and we’ll do it cheaper, faster, and smarter.”
And just like that, within four years, they’ve gone from startup to IPO. Now that’s diagnostic speed! Their hub in Thane West offers high-end tests like PET CT and MRI, while satellite centres handle the daily grind — blood tests, ultrasounds, and COVID markers (because apparently, viruses don’t believe in retirement).
This IPO aims to raise money to add five more centres across Maharashtra — part of a ₹21.11 crore capex plan for new medical equipment. Think of it as Thanos collecting diagnostic stones, each one a new centre ready to snap up customers.
But will this ambitious radiology-pathology combo scan profit or just burn cash like a bad MRI bill? Let’s diagnose that.
3. Business Model – WTF Do They Even Do?
Invicta runs on a hub-and-spoke model, which in layman terms means one big fancy centre (hub) doing all the expensive tests, and smaller branches (spokes) collecting samples and doing basic imaging. The logic? Keep the big machines busy, and the smaller units light on cost.
They operate seven locations:
One flagship hub in Thane West — full-service radiology + pathology + caffeine for the technicians.
Three mini-hubs in Bhayandar, Byculla, and Marol — mid-range testing powerhouses.
Three spokes in Lower Parel, Sewri, and Kalwa — X-rays, ultrasounds, and sample collection.
487 specialised pathology tests (molecular, immunoassay, cancer markers, genetic panels).
226 radiology tests across basic and advanced categories.
Revenue streams come mainly from direct walk-in patients, doctor referrals, and corporate health packages. Add to that their home collection model using phlebotomists (the real bloodhounds of healthcare).
Their differentiator? They combine radiology and pathology under one IT platform, meaning your MRI and your blood sugar report can now gossip in the same database.
